Vai al contenuto principale della pagina

Newborn Screening for Cystic Fibrosis



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Barben Jürg Visualizza persona
Titolo: Newborn Screening for Cystic Fibrosis Visualizza cluster
Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
Descrizione fisica: 1 electronic resource (126 p.)
Soggetto topico: Medicine
Soggetto non controllato: newborn screening
immunoreactive trypsin(ogen)
dried blood spot
radioimmunoassay
DNA
cystic fibrosis
incidence
malnutrition
cost
health policy
CF transmembrane conductance regulator-related metabolic syndrome
CF screen positive
inconclusive diagnosis
DNA analysis
next generation sequencing
extended genetic analysis
presumptive diagnosis
sweat test
parental information
newborn bloodspot screening
psychological impact
biochemical screening
pancreatitis associated protein
immunoreactive trypsinogen
cystic fibrosis screen positive
inconclusive diagnosis (CFSPID)
bioethics
newborn screen
target disorder
missed case
sensitivity
CFSPID
immunoreactive trypsin
meconium ileus
diagnosis
therapy
prognosis
Persona (resp. second.): SouthernKevin
BarbenJürg
Sommario/riassunto: The introduction and widespread implementation of newborn bloodspot screening (NBS) for cystic fibrosis (CF) has offered earlier diagnosis and better outcomes for children with CF in many countries of the world. It represents a paradigm shift in the diagnostic pathway for these families. In contrast to a clinical diagnosis, infants are now referred for diagnostic testing after a positive NBS result. The introduction of NBS has enabled the provision of early appropriate treatment to prevent the manifestations of the disease. In the near future, early diagnosis will facilitate the prompt use of new CFTR modulator therapies that correct the basic underlying molecular defect. NBS for CF has been a global success but continues to raise questions with many varied approaches and the development of new technologies, in particular the ability to undertake extensive gene examination. Which is the best protocol to achieve high sensitivity and specificity, and how to evaluate and manage infants with inconclusive diagnosis are all subjects of ongoing discussion. It is also open to question: what is the best approach to informing and counselling the parents about a positive or inconclusive NBS result? These questions are not easy to answer and require a balanced solution that reflects the local health care system and may appropriately result in different answers around the globe. The articles in this book try to answer these questions and give an overview of the current state of knowledge in NBS for CF.
Titolo autorizzato: Newborn Screening for Cystic Fibrosis  Visualizza cluster
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910557291703321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui